Ilya Pharma AB Revenue and Competitors
Estimated Revenue & Valuation
- Ilya Pharma AB's estimated annual revenue is currently $3.2M per year.
- Ilya Pharma AB's estimated revenue per employee is $201,000
Employee Data
- Ilya Pharma AB has 16 Employees.
- Ilya Pharma AB grew their employee count by -6% last year.
Ilya Pharma AB's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder | Reveal Email/Phone |
2 | Chair the Board Directors | Reveal Email/Phone |
3 | Clinical Operations Manager | Reveal Email/Phone |
4 | Clinical Operations Manager | Reveal Email/Phone |
5 | Senior Scientist | Reveal Email/Phone |
6 | PHD Student | Reveal Email/Phone |
Ilya Pharma AB Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is Ilya Pharma AB?
Ilya Pharma is a clinical stage SME developing next generation immunotherapies to treat wounds in skin and mucosa.
keywords:N/AN/A
Total Funding
16
Number of Employees
$3.2M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ilya Pharma AB News
2022-04-13 - Ilya Pharma Acquires Nordic Bioanalysis
Following the acquisition, Nordic Bioanalysis AB will continue to run at arm's length as an independent commercial entity. The aim is to expand...
2022-03-22 - Global Roundup: Oxford Hub Expanding into "Ideal ...
Hansa Biopharma AB Sweden-based Hana reached a reimbursement ... Ilya Pharma Sweden-based Ilya closed a financing round of 8.5 million...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.2M | 16 | -11% | N/A |
#2 | $1.4M | 16 | N/A | N/A |
#3 | $2.5M | 16 | 33% | $7M |
#4 | $1.9M | 16 | 23% | N/A |
#5 | $3.1M | 19 | 27% | $6M |